Equities

China Traditional Chinese Medicine Holdings Co Ltd

China Traditional Chinese Medicine Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.17
  • Today's Change-0.09 / -3.98%
  • Shares traded79.67m
  • 1 Year change-40.71%
  • Beta0.7320
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects China Traditional Chinese Med Hldg CoLtd share price to rise to 2.59 in the next year from the last price of 2.17.
High19.4%2.59
Med19.4%2.59
Low19.4%2.59

Earnings history & estimates in CNY

China Traditional Chinese Med Hldg CoLtd reported annual 2023 earnings of 0.255 per share on Mar 21, 2024.
Average growth rate+7.12%
More ▼

Revenue history & estimates in CNY

China Traditional Chinese Medicine Holdings Co. Limited had revenues for the full year 2023 of 18.12bn. This was 26.69% above the prior year's results.
Average growth rate+8.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.